EDIGENE INC.

In News

EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies - Business Wire

Business Wire - Nov 07, 2022

EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies - BioInformant

BioInformant - Feb 21, 2022

EdiGene and Arbor Biotechnologies Announce Worldwide - GlobeNewswire

GlobeNewswire - Feb 08, 2022

Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Jul 26, 2023

Top Five Privately Held Gene Editing Therapy Companies - Genetic Engineering and Biotechnology News

Genetic Engineering and Biotechnology News - May 31, 2024

EdiGene augments clinical translation of gene editing technologies - BioSpectrum Asia

BioSpectrum Asia - May 03, 2021

Trials to watch: CRISPR pipeline accelerates after milestone Casgevy approval - Clinical Trials Arena

Clinical Trials Arena - Jan 17, 2024

EdiGene, First in China Permitted to Clinical Trial Gene-Editing Tech, Banks USD61.7 Million - Yicai Global

Yicai Global - May 13, 2025

Fujifilm invests in gene therapy startup - BioPharma Dive

BioPharma Dive - Dec 21, 2017

Clinical trial: Systemic Lupus Erythematosus, SLE, (NCT06373991) - CRISPR Medicine News

CRISPR Medicine News - May 20, 2025

Chinese medicine regulator to review EdiGene’s therapy for blood disorders - Global Times

Global Times - Oct 27, 2020

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment